HE

Hisham Elhaddad

Managing Partner at HOF Capital

New York, New York

Overview 

Hisham Elhaddad is the Co-Founder and Managing Partner at HOF Capital in New York, specializing in investing in Series A and Seed stages, with a focus on IoT and AI sectors. His significant career highlights include establishing HOF Capital and successfully investing in a diverse range of innovative companies such as xAI, Anthropic, and Rimac Automobili.

Work Experience 

  • Co-Founder / Managing Partner

    2015 - Current

    HOF Capital is a multi-stage venture capital firm with $1.4B in AUM. Backed by over 200 strategic institutions, we look for relentlessly ambitious founders and help them build generational companies.

HOF Capital is a global multistage VC firm with $1 billion in AUM that partners with ambitious entrepreneurs from idea to IPO.

  • Investor

    2024

XAI is an AI company that develops a platform to accelerate human scientific discovery.

Raised $12,384,679,312.00 from Valor Equity Partners, Sequoia Capital, Andreessen Horowitz, Qatar Investment Authority and CoreNest Capital.

  • Investor

    2023

Anthropic is an AI safety and research company that focuses on increasing the safety of large-scale AI systems.

Raised $13,740,377,627.00 from Amazon.

  • Investor

    2021

  • Investor

    2020

Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.

Raised $643,000,000.00 from Alexandria Venture Investments, BlackRock, HOF Capital, CPP Investments, Google Ventures, Foresite Capital, Casdin Capital, Temasek Holdings, T. Rowe Price and Third Rock Ventures.

  • Investor, Board Member

    2020

Blank Street is a coffee chain that offers coffee as a daily ritual that more people can enjoy, in places convenient to their lives.

Raised $113,824,340.00 from General Catalyst, HOF Capital, Left Lane Capital and Tiger Global Management.

  • Investor

    2019

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.

Raised $456,973,182.00 from Novo Holdings, SymBiosis LLC, Catalio Capital Management, Leaps by Bayer, Moderna, Leaps by Bayer, Frazier Healthcare Partners, Bristol-Myers Squibb and Millennium Management.

  • Investor

    2019

UiPath is a software company that designs and develops robotic process automation and artificial intelligence applications.

Raised $1,993,025,000.00 from Turkgen Ventures.

  • Investor

    2019

BillionToOne is a precision diagnostics company that focuses on genetic testing for disease detection.

Raised $425,900,000.00 from Baillie Gifford, Civilization Ventures, Neuberger Berman, Adams Street Partners, Libertus Capital, PremjiInvest, Hummingbird Ventures and Fifty Years.

Articles About Hisham

Relevant Websites